“Umuthi oyisimangaliso wokwehlisa isisindo” usuzongena eShayina!I-Novo Nordisk China iqinisekisa ukuthi inguqulo yokulahlekelwa isisindo ye-Semaglutide izovunyelwa kulo nyaka

"Umuthi oyisimangaliso wokwehlisa isisindo" usuzongena eChina!I-Novo Nordisk China iqinisekisa ukuthi inguqulo yokulahlekelwa isisindo ye-Semaglutide izovunyelwa kulo nyaka
NgoMashi 8, izindaba zokuthi i-Novo Nordisk kulindeleke ukuthi inguqulo yokulahlekelwa isisindo ye-Semaglutide Wegovy izovunyelwa e-China kulo nyaka, umkhiqizo uzoba yisiqalo seziguli ezizixhasa ngemali, futhi kunomkhawulo wenani leziguli.Mayelana nalokhu, uNovo Nordisk China uqinisekise lezi zindaba ezingenhla entathelini yezindaba, "ibheke ngabomvu ukugunyazwa kulo nyaka, ngokushesha ngangokunokwenzeka ukuze kuzuze iziguli zokukhuluphala ngokweqile zaseShayina."

I-Wegovy igama lokuhweba lesiNgisi lomuthi we-GLP-1 i-Semaglutide owenziwe nguNovo Nordisk ngezinkomba zokuncipha kwesisindo, owavunywa njengomuthi wokwehlisa isisindo ngoJuni 2021 e-United States.I-CEO ye-Tesla u-Musk wake wakhuluma ezinkundleni zokuxhumana ukuthi usebenzise lesi sidakamizwa ukulahlekelwa isisindo, futhi wake wafunwa "njengesidakamizwa esiyisimangaliso sokulahlekelwa isisindo".

E-China, umjovo we-Semaglutide kanye nezidakamizwa zomlomo zivunyelwe kuphela izinkomba zesifo sikashukela, lapho umjovo we-simethicone uzovunyelwa ukumakethwa e-China ngo-Ephreli 2021, bese ufaka ikhathalogi kazwelonke yomshuwalense wezempilo ku-2022;I-oral Semaglutide yamukelwa ngoJanuwari kulo nyaka, futhi yaba umuthi wokuqala womlomo we-GLP-1 ovunyelwe ukumakethwa eChina.

Njengommeleli wezidakamizwa ze-GLP-1, i-Semaglutide ibe yimpumelelo kwezohwebo.Umbiko wezezimali ka-Novo Nordisk ka-2023 ubonise ukuthi ukuthengiswa kwe-Wegovy kukhuphuke ngo-406% kwaya ku-$4.6 billion, okuhola ithrekhi yomhlaba wonke ye-GLP-1.Futhi ngenxa yalokhu, izinkampani eziningi zezidakamizwa ezifuywayo zihlela ukuthuthukiswa kwezidakamizwa ze-Semaglutide biosimilar, kodwa eziningi zisesiteji sokuqala somtholampilo, njenge-Liju Group (000513), i-Han Yu Pharmaceutical (300199) nezinye izinkampani eziningi zezidakamizwa ngaphambilini zamemezela ukuthi i-Semaglutide yenkampani. umjovo uvunyelwe ukwenza izivivinyo zomtholampilo zezinkomba ezihlobene nokuphathwa kwesisindo.

Kuyafaneleka ukusho ukuthi, kanye noNovo Nordisk yaziwa ngokuthi "i-GLP-1 duo" LLY iphinde ikhuthaze ukufakwa kuhlu kwezidakamizwa ze-GLP-1 i-Tirzepatide e-China, okulindeleke ukuthi futhi zigunyazwe ngaphakathi.2023 August, LLY I-China imemezele lokho, ngokusho kwewebhusayithi esemthethweni ye-Drug Evaluation Center ye-State Drug Administration.Isicelo sokubhalisa somjovo we-Tirzepatide sokuthuthukisa ukuphathwa kwesisindo sesikhathi eside ezigulini ezikhuluphele ngokweqile ezinabantu abadala abakhuluphele noma okungenani ezine-comorbidity eyodwa ehlobene nesisindo ngesisekelo sokudla okunekhalori ephansi kanye nokuzivocavoca okwandisiwe kuye kwamukelwa ngokusemthethweni.

Inkomba yesifo sikashukela ye-Tirzepatide yavunywa e-US ngoMeyi 2022, futhi umuthi wanikela ngemali eyizigidi ezingama- $ 483 ku-Lilly ngo-2022. izinyanga ezimbili engaphansi kuka-$176 wezigidi zemali engenayo.

Njengoba kulindeleke ukuthi izidakamizwa ze-Novo Nordisk kanye ne-LLY GLP-1 zigunyazwe njengezinkomba zokuncipha kwesisindo e-China, umncintiswano phakathi kwe-Novo Nordisk ne-LLY ethrekhi ye-GLP-1 ungase uqale maduze eChina.